Palisade Bio (NASDAQ:PALI – Get Free Report) and Anavex Life Sciences (NASDAQ:AVXL – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings and dividends.
Valuation and Earnings
This table compares Palisade Bio and Anavex Life Sciences”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Palisade Bio | $250,000.00 | 13.40 | -$12.30 million | ($13.98) | -0.18 |
| Anavex Life Sciences | N/A | N/A | -$47.51 million | ($0.50) | -14.89 |
Palisade Bio has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Insider & Institutional Ownership
11.8% of Palisade Bio shares are held by institutional investors. Comparatively, 31.6% of Anavex Life Sciences shares are held by institutional investors. 3.3% of Palisade Bio shares are held by insiders. Comparatively, 11.0% of Anavex Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Palisade Bio and Anavex Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Palisade Bio | N/A | -148.51% | -115.16% |
| Anavex Life Sciences | N/A | -30.64% | -28.23% |
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Palisade Bio and Anavex Life Sciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Palisade Bio | 0 | 0 | 1 | 0 | 3.00 |
| Anavex Life Sciences | 0 | 0 | 1 | 1 | 3.50 |
Palisade Bio presently has a consensus target price of $8.00, indicating a potential upside of 217.46%. Anavex Life Sciences has a consensus target price of $40.00, indicating a potential upside of 437.27%. Given Anavex Life Sciences’ stronger consensus rating and higher possible upside, analysts clearly believe Anavex Life Sciences is more favorable than Palisade Bio.
Summary
Anavex Life Sciences beats Palisade Bio on 8 of the 12 factors compared between the two stocks.
About Palisade Bio
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.
About Anavex Life Sciences
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.
